[1] Djebali S, Davis C A, Merkel A, et al. Landscape of transcription in human cells[J]. Nature. 2012, 489(7414): 101-108.
[2] Ponting C P, Belgard T G. Transcribed dark matter: meaning or myth?[J]. Hum Mol Genet. 2010, 19(R2): R162-R168.
[3] Wang K C, Chang H Y. Molecular mechanisms of long noncoding RNAs[J]. Mol Cell. 2011, 43(6): 904-914.
[4] Sun M, Gadad S S, Kim D S, et al. Discovery, Annotation, and Functional Analysis of Long Noncoding RNAs Controlling Cell-Cycle Gene Expression and Proliferation in Breast Cancer Cells[J]. Mol Cell. 2015.
[5] Chujo T, Yamazaki T, Hirose T. Architectural RNAs (arcRNAs): A class of long noncoding RNAs that function as the scaffold of nuclear bodies[J]. Biochim Biophys Acta. 2015.
[6] Liu B, Sun L, Liu Q, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis[J]. Cancer Cell. 2015, 27(3): 370-381.
[7] Wang P, Xue Y, Han Y, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation[J]. Science. 2014, 344(6181): 310-313.
[8] Wan L B, Bartolomei M S. Regulation of imprinting in clusters: noncoding RNAs versus insulators[J]. Adv Genet. 2008, 61: 207-223.
[9] Monnier P, Martinet C, Pontis J, et al. H19 lncRNA controls gene expression of the Imprinted Gene Network by recruiting MBD1[J]. Proc Natl Acad Sci U S A. 2013, 110(51): 20693-20698.
[10] Penny G D, Kay G F, Sheardown S A, et al. Requirement for Xist in X chromosome inactivation[J]. Nature. 1996, 379(6561): 131-137.
[11] Mchugh C A, Chen C, Chow A, et al. The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3[J]. Nature. 2015, 521(7551): 232-236.
[12] Rinn J L, Kertesz M, Wang J K, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs[J]. Cell. 2007, 129(7): 1311-1323.
[13] Tsai M C, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes[J]. Science. 2010, 329(5992): 689-693.
[14] Lee J T, Davidow L S, Warshawsky D. Tsix, a gene antisense to Xist at the X-inactivation centre[J]. Nat Genet. 1999, 21(4): 400-404.
[15] Navarro P, Pichard S, Ciaudo C, et al. Tsix transcription across the Xist gene alters chromatin conformation without affecting Xist transcription: implications for X-chromosome inactivation[J]. Genes Dev. 2005, 19(12): 1474-1484.
[16] Tian D, Sun S, Lee J T. The long noncoding RNA, Jpx, is a molecular switch for X chromosome inactivation[J]. Cell. 2010, 143(3): 390-403.
[17] Vance K W, Sansom S N, Lee S, et al. The long non-coding RNA Paupar regulates the expression of both local and distal genes[J]. EMBO J. 2014, 33(4): 296-311.
[18] Yoon J H, Abdelmohsen K, Srikantan S, et al. LincRNA-p21 suppresses target mRNA translation[J]. Mol Cell. 2012, 47(4): 648-655.
[19] Carrieri C, Cimatti L, Biagioli M, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat[J]. Nature. 2012, 491(7424): 454-457.
[20] Tripathi V, Ellis J D, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation[J]. Mol Cell. 2010, 39(6): 925-938.
[21] Gutschner T, Hammerle M, Eissmann M, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells[J]. Cancer Res. 2013, 73(3): 1180-1189.
[22] Fang X Y, Pan H F, Leng R X, et al. Long noncoding RNAs: novel insights into gastric cancer[J]. Cancer Lett. 2015, 356(2 Pt B): 357-366.
[23] Bolton E M, Tuzova A V, Walsh A L, et al. Noncoding RNAs in prostate cancer: the long and the short of it[J]. Clin Cancer Res. 2014, 20(1): 35-43.
[24] Yarmishyn A A, Kurochkin I V. Long noncoding RNAs: a potential novel class of cancer biomarkers[J]. Front Genet. 2015, 6: 145.
[25] Gupta R A, Shah N, Wang K C, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis[J]. Nature. 2010, 464(7291): 1071-1076.
[26] Fu W M, Zhu X, Wang W M, et al. Hotair Mediates Hepatocarcinogenesis through Suppressing MiRNA-218 Expression and Activating P14 and P16 Signaling[J]. J Hepatol. 2015.
[27] Zhang Z Z, Shen Z Y, Shen Y Y, et al. HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly r(C)-Binding Protein (PCBP) 1[J]. Mol Cancer Ther. 2015, 14(5): 1162-1170.
[28] Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers[J]. Cancer Res. 2011, 71(20): 6320-6326.
[29] Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer[J]. Oncogene. 2013, 32(13): 1616-1625.
[30] Wang J, Chen D, He X, et al. Downregulated lincRNA HOTAIR expression in ovarian cancer stem cells decreases its tumorgeniesis and metastasis by inhibiting epithelial-mesenchymal transition[J]. Cancer Cell Int. 2015, 15: 24.
[31] Wang B, Su Y, Yang Q, et al. Overexpression of Long Non-Coding RNA HOTAIR Promotes Tumor Growth and Metastasis in Human Osteosarcoma[J]. Mol Cells. 2015, 38(5): 432-440.
[32] Zhang S, Chen S, Yang G, et al. Long noncoding RNA HOTAIR as an independent prognostic marker in cancer: a meta-analysis[J]. PLoS One. 2014, 9(8): e105538.
[33] Padua A C, Fonseca A S, Muys B R, et al. Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines[J]. Stem Cells. 2013, 31(12): 2827-2832.
[34] Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer[J]. Oncogene. 2003, 22(39): 8031-8041.
[35] Hu L, Wu Y, Tan D, et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma[J]. J Exp Clin Cancer Res. 2015, 34: 7.
[36] Yang M H, Hu Z Y, Xu C, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9[J]. Biochim Biophys Acta. 2015, 1852(1): 166-174.
[37] Pang E J, Yang R, Fu X B, et al. Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer[J]. Tumour Biol. 2015, 36(4): 2403-2407.
[38] Wu X S, Wang X A, Wu W G, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway[J]. Cancer Biol Ther. 2014, 15(6): 806-814.
[39] Han Y, Liu Y, Nie L, et al. Inducing cell proliferation inhibition, apoptosis, and motility reduction by silencing long noncoding ribonucleic acid metastasis-associated lung adenocarcinoma transcript 1 in urothelial carcinoma of the bladder[J]. Urology. 2013, 81(1): 201-209.
[40] Gabory A, Jammes H, Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development[J]. Bioessays. 2010, 32(6): 473-480.
[41] Matouk I J, Mezan S, Mizrahi A, et al. The oncofetal H19 RNA connection: hypoxia, p53 and cancer[J]. Biochim Biophys Acta. 2010, 1803(4): 443-451.
[42] Matouk I J, Halle D, Gilon M, et al. The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer[J]. J Transl Med. 2015, 13: 113.
[43] Sun H, Wang G, Peng Y, et al. H19 lncRNA mediates 17beta-estradiol-induced cell proliferation in MCF-7 breast cancer cells[J]. Oncol Rep. 2015, 33(6): 3045-3052.
[44] Huang C, Cao L, Qiu L, et al. Upregulation of H19 promotes invasion and induces epithelial-to-mesenchymal transition in esophageal cancer[J]. Oncol Lett. 2015, 10(1): 291-296.
[45] Zhou X, Yin C, Dang Y, et al. Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer[J]. Sci Rep. 2015, 5: 11516.
[46] Liu C, Chen Z, Fang J, et al. H19-derived miR-675 contributes to bladder cancer cell proliferation by regulating p53 activation[J]. Tumour Biol. 2015.
[47] Tsang W P, Ng E K, Ng S S, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer[J]. Carcinogenesis. 2010, 31(3): 350-358.
[48] Zhang X, Zhou Y, Mehta K R, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells[J]. J Clin Endocrinol Metab. 2003, 88(11): 5119-5126.
[49] Ying L, Huang Y, Chen H, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer[J]. Mol Biosyst. 2013, 9(3): 407-411.
[50] Lu K H, Li W, Liu X H, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression[J]. BMC Cancer. 2013, 13: 461.
[51] Sun M, Xia R, Jin F, et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer[J]. Tumour Biol. 2014, 35(2): 1065-1073.
[52] Yin D D, Liu Z J, Zhang E, et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer[J]. Tumour Biol. 2015.
[53] Kino T, Hurt D E, Ichijo T, et al. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor[J]. Sci Signal. 2010, 3(107): a8.
[54] Pickard M R, Williams G T. Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy[J]. Breast Cancer Res Treat. 2014, 145(2): 359-370.
[55] Shi X, Sun M, Liu H, et al. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer[J]. Mol Carcinog. 2015, 54 Suppl 1: E1-E12.
[56] Sun M, Jin F Y, Xia R, et al. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer[J]. BMC Cancer. 2014, 14: 319.
[57] Tao R, Hu S, Wang S, et al. Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma[J]. Carcinogenesis. 2015.
[58] Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response[J]. Cell. 2010, 142(3): 409-419.
[59] Yu M, Ohira M, Li Y, et al. High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma[J]. Int J Oncol. 2009, 34(4): 931-938.
[60] Zhu Y, Yu M, Li Z, et al. ncRAN, a newly identified long noncoding RNA, enhances human bladder tumor growth, invasion, and survival[J]. Urology. 2011, 77(2): 510-511.
[61] Qi P, Xu M D, Ni S J, et al. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients[J]. Mol Carcinog. 2015, 54(9): 742-750.
[62] Lee G L, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test[J]. Nat Rev Urol. 2011, 8(3): 123-124.
[63] Walsh A L, Tuzova A V, Bolton E M, et al. Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'?[J]. Trends Mol Med. 2014, 20(8): 428-436.
[64] Ifere G O, Ananaba G A. Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate- specific non-coding gene and regulator of prostate cancer progression[J]. Recent Pat DNA Gene Seq. 2009, 3(3): 151-163.
[65] Chung S, Nakagawa H, Uemura M, et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility[J]. Cancer Sci. 2011, 102(1): 245-252.
[66] Matouk I J, Abbasi I, Hochberg A, et al. Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis[J]. Eur J Gastroenterol Hepatol. 2009, 21(6): 688-692.
[67] Shao Y, Ye M, Jiang X, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer[J]. Cancer. 2014, 120(21): 3320-3328.
[68] Weber D G, Johnen G, Casjens S, et al. Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer[J]. BMC Res Notes. 2013, 6: 518. |